Woodline Partners LP Travere Therapeutics, Inc. Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
A detailed history of Woodline Partners LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 4,340,340 shares of TVTX stock, worth $80.6 Million. This represents 0.55% of its overall portfolio holdings.
Number of Shares
4,340,340
Previous 1,276,878
239.92%
Holding current value
$80.6 Million
Previous $10.5 Million
478.57%
% of portfolio
0.55%
Previous 0.11%
Shares
10 transactions
Others Institutions Holding TVTX
# of Institutions
190Shares Held
84.7MCall Options Held
681KPut Options Held
346K-
Armistice Capital, LLC New York, NY7.65MShares$142 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$142 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$128 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$86.9 Million2.23% of portfolio
-
Macquarie Group LTD Australia, C34.27MShares$79.3 Million0.07% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.19B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...